CELF4
Basic information
Region (hg38): 18:37243040-37565827
Previous symbols: [ "BRUNOL4" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CELF4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | |||||
missense | 15 | 21 | ||||
nonsense | 3 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 0 | |||||
Total | 0 | 1 | 17 | 13 | 3 |
Variants in CELF4
This is a list of pathogenic ClinVar variants found in the CELF4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
18-37259255-C-A | not specified | Uncertain significance (Feb 16, 2023) | ||
18-37264681-C-G | CELF4-related disorder | Uncertain significance (Nov 06, 2023) | ||
18-37264705-C-T | CELF4-related disorder | Benign (Dec 31, 2019) | ||
18-37264706-G-A | not specified | Uncertain significance (May 17, 2023) | ||
18-37266555-G-A | Benign (Aug 03, 2018) | |||
18-37266557-C-T | not specified | Uncertain significance (Mar 24, 2023) | ||
18-37266576-G-T | not specified | Uncertain significance (Apr 13, 2021) | ||
18-37266581-C-T | not specified | Likely benign (Sep 07, 2022) | ||
18-37270793-G-A | CELF4-related disorder | Likely benign (Aug 15, 2019) | ||
18-37270806-G-A | not specified | Uncertain significance (Jul 12, 2022) | ||
18-37270831-G-A | not specified | Uncertain significance (Sep 17, 2021) | ||
18-37270840-C-T | not specified | Likely benign (Apr 11, 2023) | ||
18-37270851-T-C | not specified | Uncertain significance (May 29, 2024) | ||
18-37270855-C-T | CELF4-related disorder | Likely benign (Feb 03, 2021) | ||
18-37270882-C-T | not specified | Uncertain significance (Dec 16, 2023) | ||
18-37270883-G-A | CELF4-related disorder | Benign (Oct 18, 2019) | ||
18-37273013-C-T | not specified | Likely benign (Jul 08, 2022) | ||
18-37273035-T-C | CELF4-related disorder | Likely benign (May 01, 2019) | ||
18-37273065-C-T | Likely benign (Apr 01, 2023) | |||
18-37273085-C-T | not specified | Likely benign (Feb 15, 2023) | ||
18-37273127-C-T | not specified | Likely benign (Feb 16, 2023) | ||
18-37273128-G-A | CELF4-related disorder | Likely benign (Jul 19, 2019) | ||
18-37273157-G-A | Uncertain significance (Jan 23, 2023) | |||
18-37274304-C-T | CELF4-related disorder | Benign (Mar 01, 2019) | ||
18-37274316-G-A | Uncertain significance (Jun 06, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CELF4 | protein_coding | protein_coding | ENST00000420428 | 12 | 322991 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.998 | 0.00183 | 125593 | 0 | 5 | 125598 | 0.0000199 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.16 | 157 | 315 | 0.499 | 0.0000179 | 3208 |
Missense in Polyphen | 59 | 152.94 | 0.38578 | 1558 | ||
Synonymous | 1.05 | 116 | 131 | 0.884 | 0.00000891 | 903 |
Loss of Function | 4.48 | 2 | 27.2 | 0.0735 | 0.00000154 | 266 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000620 | 0.0000616 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000125 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000208 | 0.0000176 |
Middle Eastern | 0.000125 | 0.000109 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: RNA-binding protein implicated in the regulation of pre- mRNA alternative splicing. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of cardiac isoforms of TNNT2 during heart remodeling at the juvenile to adult transition. Promotes exclusion of both the smooth muscle (SM) and non-muscle (NM) exons in actinin pre-mRNAs. Activates the splicing of MAPT/Tau exon 10. Binds to muscle-specific splicing enhancer (MSE) intronic sites flanking the alternative exon 5 of TNNT2 pre-mRNA. {ECO:0000269|PubMed:11158314, ECO:0000269|PubMed:12649496, ECO:0000269|PubMed:14973222, ECO:0000269|PubMed:15009664, ECO:0000269|PubMed:15894795}.;
- Pathway
- mRNA Processing
(Consensus)
Recessive Scores
- pRec
- 0.118
Intolerance Scores
- loftool
- 0.344
- rvis_EVS
- -0.51
- rvis_percentile_EVS
- 21.41
Haploinsufficiency Scores
- pHI
- 0.516
- hipred
- Y
- hipred_score
- 0.743
- ghis
- 0.688
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.731
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Celf4
- Phenotype
- embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); vision/eye phenotype; immune system phenotype; homeostasis/metabolism phenotype; growth/size/body region phenotype; endocrine/exocrine gland phenotype; muscle phenotype;
Gene ontology
- Biological process
- alternative mRNA splicing, via spliceosome;regulation of alternative mRNA splicing, via spliceosome;mRNA splice site selection;germ cell development;embryo development ending in birth or egg hatching;negative regulation of translation;negative regulation of mRNA splicing, via spliceosome;positive regulation of mRNA splicing, via spliceosome;negative regulation of excitatory postsynaptic potential;regulation of retina development in camera-type eye
- Cellular component
- nucleus;cytoplasm;ribonucleoprotein complex
- Molecular function
- translation repressor activity, mRNA regulatory element binding;RNA binding;mRNA binding;pre-mRNA binding;BRE binding